Effective antibacterials: at what cost? The economics of antibacterial resistance and its control

Research output: Contribution to journalArticlepeer-review

Standard

Effective antibacterials : at what cost? The economics of antibacterial resistance and its control. / White, Anthony R; BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development ; Piddock, Laura.

In: Journal of Antimicrobial Chemotherapy, Vol. 66, No. 9, 09.2011, p. 1948-53.

Research output: Contribution to journalArticlepeer-review

Harvard

White, AR, BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development & Piddock, L 2011, 'Effective antibacterials: at what cost? The economics of antibacterial resistance and its control', Journal of Antimicrobial Chemotherapy, vol. 66, no. 9, pp. 1948-53. https://doi.org/10.1093/jac/dkr260

APA

White, A. R., BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development, & Piddock, L. (2011). Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. Journal of Antimicrobial Chemotherapy, 66(9), 1948-53. https://doi.org/10.1093/jac/dkr260

Vancouver

White AR, BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development, Piddock L. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. Journal of Antimicrobial Chemotherapy. 2011 Sep;66(9):1948-53. https://doi.org/10.1093/jac/dkr260

Author

White, Anthony R ; BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development ; Piddock, Laura. / Effective antibacterials : at what cost? The economics of antibacterial resistance and its control. In: Journal of Antimicrobial Chemotherapy. 2011 ; Vol. 66, No. 9. pp. 1948-53.

Bibtex

@article{f4ee4bffe4e640cda0b6ae323e52bbd6,
title = "Effective antibacterials: at what cost? The economics of antibacterial resistance and its control",
abstract = "The original and successful business model of return on investment being sufficiently attractive to the pharmaceutical industry to encourage development of new antibacterial molecules and related diagnostics has been compromised by increasing development costs and regulatory hurdles, resulting in a decreasing chance of success and financial return. The supply of new effective agents is diminishing along with the number of companies engaged in antibacterial research and development. The BSAC Working Party on The Urgent Need:Regenerating Antibacterial Drug Discovery and Development identified the need to establish, communicate and apply the true health and economic value of antibacterials, along with the adoption of meaningful incentives, as part of the future model for antibacterial development. Robust data are needed on the cost of resistance and ineffective treatment of bacterial infection, along with national and local holistic analyses of the cost-benefit of antibacterials. An understanding of the true health and economic value of antibacterials and the cost of resistance across healthcare systems needs to be generated, communicated and used in order to set a pricing and reimbursement structure that is commensurate with value. The development and economic model of antibacterial use needs to be rebuilt based on this value through dialogue with the various stakeholders, including the pharmaceutical industry, and alternative incentives from 'push' to 'pull' and funding models, such as public/private partnerships, agreed. A research and development model that succeeds in developing and delivering new antibacterial agents that address the health needs of society from start to finish, 'from cradle to grave', must be established.",
keywords = "Anti-Bacterial Agents, Bacterial Infections, Cost-Benefit Analysis, Drug Discovery, Drug Industry, Drug Resistance, Bacterial, Humans, Models, Theoretical",
author = "White, {Anthony R} and {BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development} and Laura Piddock",
year = "2011",
month = sep,
doi = "10.1093/jac/dkr260",
language = "English",
volume = "66",
pages = "1948--53",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "9",

}

RIS

TY - JOUR

T1 - Effective antibacterials

T2 - at what cost? The economics of antibacterial resistance and its control

AU - White, Anthony R

AU - BSAC Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development

AU - Piddock, Laura

PY - 2011/9

Y1 - 2011/9

N2 - The original and successful business model of return on investment being sufficiently attractive to the pharmaceutical industry to encourage development of new antibacterial molecules and related diagnostics has been compromised by increasing development costs and regulatory hurdles, resulting in a decreasing chance of success and financial return. The supply of new effective agents is diminishing along with the number of companies engaged in antibacterial research and development. The BSAC Working Party on The Urgent Need:Regenerating Antibacterial Drug Discovery and Development identified the need to establish, communicate and apply the true health and economic value of antibacterials, along with the adoption of meaningful incentives, as part of the future model for antibacterial development. Robust data are needed on the cost of resistance and ineffective treatment of bacterial infection, along with national and local holistic analyses of the cost-benefit of antibacterials. An understanding of the true health and economic value of antibacterials and the cost of resistance across healthcare systems needs to be generated, communicated and used in order to set a pricing and reimbursement structure that is commensurate with value. The development and economic model of antibacterial use needs to be rebuilt based on this value through dialogue with the various stakeholders, including the pharmaceutical industry, and alternative incentives from 'push' to 'pull' and funding models, such as public/private partnerships, agreed. A research and development model that succeeds in developing and delivering new antibacterial agents that address the health needs of society from start to finish, 'from cradle to grave', must be established.

AB - The original and successful business model of return on investment being sufficiently attractive to the pharmaceutical industry to encourage development of new antibacterial molecules and related diagnostics has been compromised by increasing development costs and regulatory hurdles, resulting in a decreasing chance of success and financial return. The supply of new effective agents is diminishing along with the number of companies engaged in antibacterial research and development. The BSAC Working Party on The Urgent Need:Regenerating Antibacterial Drug Discovery and Development identified the need to establish, communicate and apply the true health and economic value of antibacterials, along with the adoption of meaningful incentives, as part of the future model for antibacterial development. Robust data are needed on the cost of resistance and ineffective treatment of bacterial infection, along with national and local holistic analyses of the cost-benefit of antibacterials. An understanding of the true health and economic value of antibacterials and the cost of resistance across healthcare systems needs to be generated, communicated and used in order to set a pricing and reimbursement structure that is commensurate with value. The development and economic model of antibacterial use needs to be rebuilt based on this value through dialogue with the various stakeholders, including the pharmaceutical industry, and alternative incentives from 'push' to 'pull' and funding models, such as public/private partnerships, agreed. A research and development model that succeeds in developing and delivering new antibacterial agents that address the health needs of society from start to finish, 'from cradle to grave', must be established.

KW - Anti-Bacterial Agents

KW - Bacterial Infections

KW - Cost-Benefit Analysis

KW - Drug Discovery

KW - Drug Industry

KW - Drug Resistance, Bacterial

KW - Humans

KW - Models, Theoretical

U2 - 10.1093/jac/dkr260

DO - 10.1093/jac/dkr260

M3 - Article

C2 - 21700625

VL - 66

SP - 1948

EP - 1953

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 9

ER -